Tony Butler – Roth Capital

Roth Capital

A Roth Capital analyst with 8 tracked ratings across 8 distinct tickers has a 50% success rate on the captured sample, covering sources in two categories.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

4 years ago

2022-06-02 00:00:00+00

Track record

Aggregated

50% success rate

Bullish: 3
Hold: 4
Bearish: 2

Aggregated

Not available

Bullish: 0
Hold: 1
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
RAIN	2022-06-02	buy	$16.00	Aggregated
RAINRAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. CLASS A COMMON STOCK	2022-06-02	unknown	$16.00	Aggregated
MRKR	2022-02-17	hold	$1.00	Aggregated
MRKRMARKER THERAPEUTICS INC	2022-02-17	hold	$1.00	Aggregated
GTHX	2021-09-01	buy	$56.00	Aggregated
GTHXG1 THERAPEUTICS INC	2021-09-01	unknown	$56.00	Aggregated
TBIO	2021-08-04	hold	$38.00	Aggregated
TBIOTELESIS BIO INC	2021-08-04	hold	$38.00	Aggregated
BCAB	2021-06-28	sell	$75.00	Aggregated
BCABBIOATLA INC	2021-06-28	unknown	$75.00	Aggregated
NTLA	2021-06-28	sell	$110.00	Aggregated
NTLAINTELLIA THERAPEUTICS INC	2021-06-28	unknown	$110.00	Aggregated
PBLA	2021-06-28	buy	$10.00	Aggregated
PBLA-	2021-06-28	unknown	$10.00	Aggregated

Tickers covered(14)

Ticker	Ratings	Last rating	Sources
RAIN	2	2022-06-02	Aggregated
RAINRAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC. CLASS A COMMON STOCK	1	2022-06-02	Aggregated
MRKR	2	2022-02-17	Aggregated
MRKRMARKER THERAPEUTICS INC	1	2022-02-17	Aggregated
GTHX	2	2021-09-01	Aggregated
GTHXG1 THERAPEUTICS INC	1	2021-09-01	Aggregated
TBIO	1	2021-08-04	Aggregated
TBIOTELESIS BIO INC	1	2021-08-04	Aggregated
BCAB	2	2021-06-28	Aggregated
BCABBIOATLA INC	1	2021-06-28	Aggregated
NTLA	2	2021-06-28	Aggregated
NTLAINTELLIA THERAPEUTICS INC	1	2021-06-28	Aggregated
PBLA	2	2021-06-28	Aggregated
PBLA-	1	2021-06-28	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.